Discovery of new inhibitors of resistant Streptococcus pneumoniae Penicillin Binding Protein (PBP) 2x by structure-based virtual screening

Journal of Medicinal Chemistry

Volumn 52, Issue 19, 2009, Pages 5926-5936

  Miguet, Laurence ^a   Zervosen, Astrid ^b   Gerards, Thomas ^b   Pasha, Farhan A ^a   Luxen, André ^b   Distéche Nguyen, Martine ^b   Thomas, Aline ^a  

^a INSTITUT DE BIOLOGIE STRUCTURALE   (France)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

PENICILLIN BINDING PROTEIN;

ARTICLE; CRYSTAL STRUCTURE; MOLECULAR MODEL; PHARMACOPHORE; STREPTOCOCCUS PNEUMONIAE;

COMPUTATIONAL BIOLOGY; COMPUTER SIMULATION; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, BACTERIAL; LIGANDS; PENICILLIN-BINDING PROTEINS; PROTEIN BINDING; STREPTOCOCCUS PNEUMONIAE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 70349816746     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900625q     Document Type: Article

References (61)

1. Rogers, H. J. Bacterial Growth and Cell Envelope. Bacteriol. Rev. 1970, 34, 194-214.
2. Barreteau, H.; Kovač, A.; Boniface, A.; Sova, M.; Gobec, S.; Blanot, D. Cytoplasmic steps of peptidoglycan biosynthesis. Fems Microbiology Reviews 2008, 32, 168-207.
3. Vollmer, W.; Blanot, D.; de Pedro, M. A. Peptidoglycan structure and architecture. FEMS Microbiol. Rev. 2008, 32, 149-167.
4. Kernodle, D. S. Gram-Positive Pathogens; American Society for Microbiology: Washington DC, 2000; pp 609-620.
5. Koch, A. L. Bacterial wall as target for attack: past, present, and future research. Clin. Microbiol. Rev. 2003, 16, 673-687.
6. Zapun, A.; Contreras-Martel, C.; Vernet, T. Penicillin-binding proteins and beta-lactam resistance. FEMS Microbiol. Rev. 2008, 32, 361-385.
7. Laible, G.; Hakenbeck, R. Penicillin-Binding Proteins in Beta- Lactam-Resistant Laboratory Mutants of Streptococcus pneumoniae. Mol. Microbiol. 1987, 1, 355-363.
8. Laible, G.; Hakenbeck, R. 5 Independent Combinations of Mutations Can Result in Low-Affinity Penicillin-Binding Protein-2x of Streptococcus pneumoniae. J. Bacteriol. 1991, 173, 6986-6990.
9. Grebe, T.; Hakenbeck, R. Penicillin-binding proteins 2b and 2x of Streptococcus pneumoniae are primary resistance determinants for different classes of beta-lactam antibiotics. Antimicrob. Agents Chemother. 1996, 40, 829-834.
10. Nagai, K.; Davies, T. A.; Jacobs, M. R.; Appelbaum, P. C. Effects of amino acid alterations in penicillin-binding proteins (PBPs) 1a, 2b, and 2x on PBP affinities of penicillin, ampicillin, amoxicillin, cefditoren, cefuroxime, cefprozil, and cefaclor in 18 clinical isolates of penicillin-susceptible, -intermediate, and -resistant pneumococci. Antimicrob. Agents Chemother. 2002, 46, 1273-1280.
11. Macheboeuf, P.; Contreras-Martel, C.; Job, V.; Dideberg, O.; Dessen, A. Penicillin binding proteins: key players in bacterial cell cycle and drug resistance processes. FEMS Microbiol. Rev. 2006, 30, 673-691.
12. Pares, S.; Mouz, N.; Pétillot, Y.; Hakenbeck, R.; Dideberg, O. X-ray structure of Streptococcus pneumoniae PBP2x, a primary penicillin target enzyme. Nat. Struct. Biol. 1996, 3, 284-289.
13. Gordon, E.; Mouz, N.; Duee, E.; Dideberg, O. The crystal structure of the penicillin-binding protein 2x from Streptococcus pneumoniae and its acyl-enzyme form: implication in drug resistance. J. Mol. Biol. 2000, 299, 477-485.
14. Dessen, A.; Mouz, N.; Gordon, E.; Hopkins, J.; Dideberg, O. Crystal structure of PBP2x from a highly penicillin-resistant Streptococcus pneumoniae clinical isolate: a mosaic framework containing 83 mutations. J. Biol. Chem. 2001, 276, 45106-45112.
15. Chesnel, L.; Pernot, L.; Lemaire, D.; Champelovier, D.; Croize, J.; Dideberg, O.; Vernet, T.; Zapun, A. The structural modifications induced by the M339F substitution in PBP2x from Streptococcus pneumoniae further decreases the susceptibility to beta-lactams of resistant strains. J. Biol. Chem. 2003, 278, 44448-44456.
16. Pernot, L.; Chesnel, L.; Le Gouellec, A.; Croize, J.; Vernet, T.; Dideberg, O.; Dessen, A. A PBP2x from a clinical isolate of Streptococcus pneumoniae exhibits an alternative mechanism for reduction of susceptibility to beta-lactam antibiotics. J. Biol. Chem. 2004, 279, 16463-16470.
17. Yamada, M.; Watanabe, T.; Miyara, T.; Baba, N.; Saito, J.; Takeuchi, Y.; Ohsawa, F. Crystal structure of cefditoren complexed with Streptococcus pneumoniae penicillin-binding protein 2X: structural basis for its high antimicrobial activity. Antimicrob. Agents Chemother. 2007, 51, 3902-3907.
18. Yamada, M.; Watanabe, T.; Baba, N.; Takeuchi, Y.; Ohsawa, F.; Gomi, S. Crystal structures of biapenem and tebipenem complexed with penicillin-binding proteins 2X and 1A from Streptococcus pneumoniae. Antimicrob. Agents Chemother. 2008, 52, 2053-2060.
19. Chesnel, L.; Carapito, R.; Croize, J.; Dideberg, O.; Vernet, T.; Zapun, A. Identical penicillin-binding domains in penicillin-binding proteins of Streptococcus pneumoniae clinical isolates with different levels of beta-lactam resistance. Antimicrob. Agents Chemother. 2005, 49, 2895-2902.
20. Waxman, D. J.; Strominger, J. L. Penicillin-Binding Proteins and the Mechanism of Action of Beta-Lactam Antibiotics. Annu. Rev. Biochem. 1983, 52, 825-869.
21. Oliva, M.; Dideberg, O.; Field, M. J. Understanding the acylation mechanisms of active-site serine penicillin-recognizing proteins: a molecular dynamics simulation study. Proteins 2003, 53, 88-100.
22. Kobayashi, R.; Konomi, M.; Hasegawa, K.; Morozumi, M.; Sunakawa, K.; Ubukata, K. In vitro activity of tebipenem, a new oral carbapenem antibiotic, against penicillin-nonsusceptible Streptococcus pneumoniae. Antimicrob. Agents Chemother. 2005, 49, 889-894.
23. Aszodi, J.; Rowlands, D. A.; Mauvais, P.; Collette, P.; Bonnefoy, A.; Lampilas, M. Design and synthesis of bridged gamma-lactams as analogues of beta-lactam antibiotics. Bioorg. Med. Chem. Lett. 2004, 14, 2489-2492.
24. Jungheim, L. N.; Boyd, D. B.; Indelicato, J. M.; Pasini, C. E.; Preston, D. A.; Alborn, W. E., Jr. Synthesis, hydrolysis rates, supercomputer modeling, and antibacterial activity of bicyclic tetrahydropyridazinones. J. Med. Chem. 1991, 34, 1732-1739.
25. Zervosen, A.; Lu, W. P.; Chen, Z.; White, R. E.; Demuth, T. P., Jr.; Frere, J. M. Interactions between penicillin-binding proteins (PBPs) and two novel classes of PBP inhibitors, arylalkylidene rhodanines and arylalkylidene iminothiazolidin-4-ones. Antimicrob. Agents Chemother. 2004, 48, 961-969.
26. Nozaki, Y.; Katayama, N.; Harada, S.; Ono, H.; Okazaki, H. Lactivicin, a naturally occurring non-beta-lactam antibiotic having beta-lactam-like action: biological activities and mode of action. J Antibiot. (Tokyo) 1989, 42, 84-93.
27. Macheboeuf, P.; Fischer, D. S.; Brown, T.; Zervosen, A.; Luxen, A.; Joris, B.; Dessen, A.; Schofield, C. J. Structural and mechanistic basis of penicillin-binding protein inhibition by lactivicins. Nature Chem. Biol. 2007, 3, 565-569.
28. Kovač, A.; Konc, J.; Vehar, B.; Bostock, J. M.; Chopra, I.; Janežič, D.; Gobec, S. Discovery of New Inhibitors of D-Alanine:D-Alanine Ligase by Structure-Based Virtual Screening. J. Med. Chem. 2008, 51, 7442-7448.
29. Besong, G. E.; Bostock, J. M.; Stubbings, W.; Chopra, I.; Roper, D. I.; Lloyd, A. J.; Fishwick, C. W.; Johnson, A. P. A de novo designed inhibitor of D-Ala-D-Ala ligase from E. coli. Angew. Chem., Int. Ed. 2005, 44, 6403-6406.
30. Rarey, M.; Kramer, B.; Lengauer, T.; Klebe, G. A fast flexible docking method using an incremental construction algorithm. J. Mol. Biol. 1996, 261, 470-489.
31. Carapito, R.; Chesnel, L.; Vernet, T.; Zapun, A. Pneumococcal beta-lactam resistance due to a conformational change in penicillin- binding protein 2x. J. Biol. Chem. 2006, 281, 1771-1777.
32. Josephine, H. R.; Charlier, P.; Davies, C.; Nicholas, R. A.; Pratt, R. F. Reactivity of penicillin-binding proteins with peptidoglycanmimetic beta-lactams: what's wrong with these enzymes? Biochemistry 2006, 45, 15873-15883.
33. Wallace, A. C.; Laskowski, R. A.; Thornton, J. M. Ligplot: A Program to Generate Schematic Diagrams of Protein Ligand Interactions. Protein Eng. 1995, 8, 127-134.
34. Dessen, A.; Mouz, N.; Gordon, E.; Hopkins, J.; Dideberg, O. Crystal structure of PBP2x from a highly penicillin-resistant Streptococcus pneumoniae clinical isolate: a mosaic framework containing 83 mutations. J. Biol. Chem. 2001, 276, 45106-45112.
35. David, L.; Aadal Nielsen, M.; Hedström, M.; Nordén, B. Scope and Limitation of Ligand Docking: Methods, Scoring Functions and Protein Targets. Curr. Comput.-Aided Drug Des. 2005, 1, 65-72.
36. Hritz, J.; de Ruiter, A.; Ostenbrink, C. Impact of Plasticity and Flexibility on Docking Results for Cytochrome P450 2D6: A Combined Approach of Molecular Dynamics and Ligand Docking. J. Med. Chem. 2008, 51, 7469-7477.
37. Pinto, I. G.; Guilbert, C.; Ulyanov, N. B.; Stearns, J.; James, T. L. Discovery of Ligands for a Novel Target, the Human Telomerase RNA, Based on Flexible-Target Virtual Screening and NMR. J. Med. Chem. 2008, 51, 7205-7215.
38. Kokh, D. B.; Wenzel, W. G. Flexible side chain models improve enrichment rates in in silico screening. J. Med. Chem. 2008, 51, 5919-5931.
39. Sotriffer, C. A.; Dramburg, I. "In situ cross-docking" to simultaneously address multiple targets. J. Med. Chem. 2005, 48, 3122-3125.
40. Sali, A.; Blundell, T. L. Comparative Protein Modeling by Satisfaction of Spatial Restraints. J. Mol. Biol. 1993, 234, 779-815.
41. Davis, I. W.; Leaver-Fay, A.; Chen, V. B. B.; J., N.; Kapral, G. K.; Wang, X.; Murray, L. W.; Arendall, W. B., III; Snoeyink, J.; Richardson, J. S.; Richardson, D. C. MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res. 2007, 35, 375-383.
42. Spangler, S. K.; Jacobs, M. R.; Appelbaum, P. C. MIC and time-kill studies of antipneumococcal activity of CV 118819X (Sanfetrinem) compared with those of other agents. Antimicrob. Agents Chemother. 1997, 41, 148-155.
43. Schwyzer, R.; Hurlimann, C.; Coenzyle, C. Model reactions of the enzymic activation of acyl derivatives of coenzyme A. Helv. Chim. Acta 1954, 37, 155-166.
44. Adam, M.; Damblon, C.; Plaitin, B.; Christiaens, L.; Frere, J. M. Chromogenic Depsipeptide Substrates for Beta-Lactamases and Penicillin-Sensitive Dd-Peptidases. Biochem. J. 1990, 270, 525-529.
45. Jones, R. N.; Sader, H. S.; Stilwell, M. G.; Fritsche, T. R. Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae. Diagn. Microbiol. Infect. Dis. 2007, 58, 1-7.
46. SYBYL7.2; Tripos International: 1699 South Hanley Rd., St. Louis, MO, 63144.
47. Hindle, S. A.; Rarey, M.; Buning, C.; Lengauer, T. Flexible docking under pharmacophore type constraints. J. Comput.-Aided Mol. Des. 2002, 16, 129-149.
48. Irwin, J. J.; Shoichet, B. K. ZINC; a free database of commercially available compounds for virtual screening. J. Chem. Inf. Model. 2005, 45, 177-182.
49. Shoichet, B. K. Screening in a spirit haunted world. Drug Discovery Today 2006, 11, 607-615.
50. Feng, B. Y.; Shoichet, B. K. A detergent-based assay for the detection of promiscuous inhibitorsS. Nat. Protoc. 2006, 1, 550-553.
51. Zervosen, A.; Lu, W. P.; Chen, Z.; White, R. E.; Demuth, T. P., Jr.; Frere, J. M. Interactions between penicillin-binding proteins (PBPs) and two novel classes of PBP inhibitors, arylalkylidene rhodanines and arylalkylidene iminothiazolidin-4-ones. Antimicrob. Agents Chemother. 2004, 48, 961-969.
52. Jamin, M.; Hakenbeck, R.; Frere, J. M. Penicillin binding protein 2x as a major contributor to intrinsic beta-lactam resistance of Streptococcus pneumoniae. FEBS Lett. 1993, 331, 101-104. (Pubitemid 23285634)
53. Josephine, H. R.; Charlier, P.; Davies, C.; Nicholas, R. A.; Pratt, R. F. Reactivity of penicillin-binding proteins with peptidoglycanmimetic beta-lactams: what's wrong with these enzymes? Biochemistry 2006, 45, 15873-15883.
54. Kaminski, G. A.; Friesner, R. A.; Tirado-Rives, J.; Jorgensen, W. L. Evaluation and reparametrization of the OPLS-AA force field for proteins via comparison with accurate quantum chemical calculations on peptides. J. Phys. Chem. B 2001, 105, 6474-6487.
55. LIGPREP-2.211; Schrödinger LLC: New York, 2005.
56. Shelley, J. C.; Cholletti, A.; Frye, L. L.; Greenwood, J. R.; Timlin, M. R.; Uchimaya, M. Epik: a software program for pKa prediction and protonation state generation for drug-like molecules. J. Comput.- Aided Mol. Des. 2007, 21, 681-691.
57. Dixon, S. L.; Smondyrev, A. M.; Rao, S. N. PHASE: A novel approach to pharmacophore modeling and 3D database searching. Chem. Biol. Drug Des. 2006, 67, 370-372.
58. Thompson, J. D.; Higgins, D. G.; Gibson, T. J. Clustal- W; Improving the Sensitivity of Progressive Multiple Sequence Alignment through Sequence Weighting, Position-Specific Gap Penalties, and Weight Matrix Choice. Nucleic Acids Res. 1994, 22, 4673-4680.
59. Cornell, W. D.; Cieplak, P.; Bayly, C. I.; Gould, I. R.; Merz, K. M.; Ferguson, D. M.; Spellmeyer, D. C.; Fox, T.; Caldwell, J. W.; Kollman, P. A. A 2nd Generation Force-Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules. J. Am. Chem. Soc. 1995, 117, 5179-5197.
60. Wang, J.; Cieplak, P.; Kollman, P. A. How well does a restrained electrostatic potential (RESP) model perform in calculating conformational energies of organic and biological molecules? J. Comput. Chem. 1999, 21, 1049-1974.
61. Lakaye, B.; Damblon, C.; Jamin, M.; Galleni, M.; Lepage, S.; Joris, B.; Marchandbrynaert, J.; Frydrych, C.; Frere, J. M. Synthesis, Purification, and Kinetic Properties of Fluorescein-Labeled Penicillins. Biochem. J. 1994, 300, 141-145. (Pubitemid 24151029)